Previous results from our laboratory demonstrated that purified lymphocytosis-promoting factor (LPF), a protein toxin from Bordetella pertussis, inhibited the migration of murine macrophages in vitro. The current study examined the in vivo effects of LPF on mononuclear phagocyte circulation and response to an inflammatory stimulus. Intravenous injection of mice with 200 ng of LPF produced a prolonged monocytosis which peaked with a fivefold increase on day 5 after injection. LPF (200 ng) also inhibited by more than 75% the increase in peritoneal inflammatory macrophages induced by intraperitoneal injection of thioglycolate broth, phytohemagglutinin, or paraffin oil. The inhibition was significant when thioglycolate was given 1 h or 2 or 4 days after LPF but not when thioglycolate was given 2 or 4 days before LPF. The LPF-induced monocytosis on day 5 after injections was not altered by the intraperitoneal injection of thioglycolate broth. The leukocytosis-promoting and macrophage-inhibiting properties of LPF were the same in N:NIH(S) and C3H/HeJ mice. Treatments of LPF that reduced the leukocytosis-promoting effect of LPF also reduced the ability of LPF to inhibit the macrophage response. LPF doses sufficient to induce leukocytosis (.25 ng) significantly inhibited the thioglycolate-induced increase in peritoneal macrophages. The results indicate that coincident with an LPF-induced monocytosis is a reduction in the number of mononuclear phagocytes at a site of inflammation. An in vivo inhibition of mononuclear phagocyte migration would explain both effects of LPF and is consistent with the in vitro inhibition of macrophage migration by LPF.
Bordetella pertussis, the agent of human pertussis, is a highly successful respiratory pathogen. The organism has a very high attack rate; ca. 90% of susceptible individuals exposed to a case in a home will become infected (20). Additionally, without antibiotic intervention, the infection can persist in an individual for 3 to 8 weeks (6, 29) . Such success implies that B. pertussis possesses effective mechanisms to resist host defenses. To define some of these mechanisms, we studied the interactions between B. pertussis and mononuclear phagocytes (MNPs). MNPs were selected because alveolar macrophages have been shown to be of major importance in lung defense (10, 12) . Additionally, the studies of Cheers and Gray (7) in a murine model system in which intranasal infection with B. pertussis was used suggested that viable B. pertussis remained associated with alveolar macrophages for a prolonged period.
Initial studies focused on the effects of purified lymphocytosis-promoting factor (LPF) on MNP function. LPF (synonyms: pertussis toxin, pertussigen, islet-activating protein, and histamine-sensitizing factor) is a major protein toxin of B. pertussis which, when injected into experimental animals, induces a lymphocytosis and a leukocytosis, sensitizes animals to the lethal effects of histamine, enhances insulin release, attenuates epinephrine-induced hyperglycemia, and is an immunological adjuvant (24, 27, 41) . There is evidence that LPF is responsible for some of the systemic manifestations of B. pertussis infection (30, 40) . Recent experiments in a murine respiratory infection model (9, 33) showed that LPF may also be important in establishing or maintaining the localized respiratory infection. In these experiments, mice previously immunized actively with LPF or passively with antibodies to LPF were challenged with aerosols of B. pertussis. Immunized mice had fewer viable * Corresponding author. organisms in the lung and cleared the infection earlier than did nonimmunized mice.
Recent in vitro studies demonstrated that LPF profoundly inhibited macrophage migration, but had little or no effect on viability, attachment, phagocytosis, or superoxide production (19) . Other workers have reported that MNPs or polymorphonuclear leukocytes (PMNs) in animals treated with either B. pertussis cells or cell extracts migrated poorly into sites of localized inflammation (1, 13, 17) . The work reported here will show that purified LPF is responsible for the inhibition of the migration of MNPs into a site of inflammation. In addition, it was observed that LPF increased the blood monocyte count both in the presence and absence of an acute inflammatory response.
(A preliminary report of this work was presented at the 19th National Meeting of the Reticuloendothelial Society, October 1982.)
MATERIALS AND METHODS
Mice. Female mice 6 to 12 weeks of age were used for all experiments. N:NIH(S) mice were obtained from the Division of Research Resources of the National Institutes of Health (Bethesda, Md.). C3H/HeJ mice were purchased from the Jackson Laboratories (Bar Harbor, Maine), housed in a laminar-flow biological safety cabinet, and fed autoclaved food and water.
LPF. LPF was purified from supernatant fluids of cultures of B. pertussis 165 and was shown to migrate as a single band on polyacrylamide gel electrophoresis (34) . The preparation contained less than 0.02% (wt/wt) of either endotoxin or B. pertussis extracytoplasmic adenylate cyclase (19 Blood leukocyte counts. Peripheral blood (10 ,ul) was obtained from the tail vein and added to 10 ml of Isoton diluting fluid (Coulter Electronics, Hialeah, Fla.). Total counts, expressed as leukocytes per cubic millimeter of venous blood, were determined in a Coulter Counter (model Z-BI; Coulter Electronics). Differential counts were determined on peroxidase-stained blood smears counterstained with Diff-Quik (American Scientific Products, McGaw Park, Ill.). Monocytes were identified as peroxidase-positive mononuclear cells. At least 200 cells were counted for each control mouse, and at least 400 cells were counted for each LPF-treated mouse. Each mouse was used at only one time point during an experiment.
Peritoneal leukocyte counts. Mice treated under protocols described in the text were killed by inhalation of CO2. The skin was removed to expose the peritoneal cavity, and exactly 7 ml of PBS containing 10 U of heparin (O'Neal, Jones, and Feldman, Inc., Div. of Chromalloy Pharmaceuticals, St. Louis, Mo.) per ml was vigorously injected into the peritoneal cavity. After massage of the peritoneum, a 4-to 5-ml sample of the lavage fluid was removed, and the total leukocytes per milliliter was determined in a Coulter Counter for each mouse in the experiment. The count of leukocytes per milliliter was multiplied by the 7-ml injection volume to estimate the peritoneal leukocytes per mouse. This method assumes a small, constant peritoneal fluid volume and that lavage produces a uniform suspension of cells in the peritoneal cavity, and it was found to be more reproducible than assuming total recovery of cells by multiple peritoneal washes.
Differential counts were determined on a pool of cells prepared by mixing equal volumes of the lavage fluids from each of the mice in a given experimental group. A slide of the cells in this pool was prepared in a Shandon Cytospin (Shandon Southern Instruments, Sewickley, Pa.) and stained with Diff-Quik. Differential counts, based on morphological criteria, were made by counting at least 200 cells. The average peritoneal macrophage count per mouse in a given experimental group was calculated by multiplying the average number of peritoneal leukocytes per mouse by the fraction of macrophages in the group determined in the differential count. Erythrocyte contamination was observed in the lavage fluids in a small percentage (less than 10%) of the mice which received an inflammatory stimulus, and peritoneal macrophage counts were determined individually for each of these mice. Counts from these mice were included in the calculations because the results were the same whether or not these results were included.
Inflammatory agents. A peritoneal inflammatory response was induced by the i.p. injection of one of the following agents: 2.5 ml of Brewer thioglycolate broth (TGB, no. 21196; BBL Microbiology Systems, Cockeysville, Md.), 0.4 ml of paraffin oil (Fisher Scientific, Fairlawn, N.J.), or 0.5 ml of a 1:5 dilution of phytohemagglutinin (PHA, no. 79-150; Miles-Yeda Ltd., Rehovot, Israel) in PBS.
APM. The increase in peritoneal macrophage number induced by intraperitoneal (i.p.) injection of an inflammatory agent was estimated by subtracting the mean macrophage count of four to seven mice which did not receive the agent from the mean macrophage count of four to seven mice which were injected with the inflammatory agent. This difference represents the inflammatory agent-induced accumulation of peritoneal macrophages (APM).
Antibodies specific for LPF. Serum was obtained from goats hyperimmunized with purified LPF emulsified in complete Freund adjuvant. The immunoglobulin G (IgG) fraction was obtained by fractionation of the serum on DEAESephacel (Pharmacia Fine Chemicals, Piscataway, N.J.), using a procedure published by the manufacturer (Pharmacia Separation News, vol. 5, 1980) . Statistical analysis. Results from experimental groups were compared by using the Student t test. RESULTS LPF: a monocytosis-promoting factor. Figure 1 shows the blood leukocyte responses in N:NIH(S) mice during the 7-day period after a single i.v. injection of 200 ng of LPF. Shown are the counts of monocytes, lymphocytes, PMNs, and total leukocytes per cubic millimeter of venous blood. This LPF dose (200 ng) was chosen in preliminary experiments because it induced a nearly maximal leukocytosis but exhibited no toxicity as assessed by weight loss or death. Control mice injected with PBS had stable base-line values for all classes of leukocytes during the 7-day test period. The mean differential count for the control mice in the experiment was 74.3% lymphocytes, 4.7% monocytes, and 21.0%
PMNs. The results demonstrate that LPF induced a greater-than-fivefold increase in the absolute number of monocytes, lymphocytes, and PMNs during the 7 days after LPF administration ( Fig. 1 ). This result had been reported for' lymphocytes and PMNs (24) , but is a new observation for monocytes. Though all classes of blood leukocytes were affected, there were differences in the kinetics among the three classes. The number of lymphocytes increased rapidly during the first 24 h, peaked at 3 days, and fell thereafter. The PMNs and monocytes, however, responded more slowly and increased gradually to a peak at day 5.
Inhibition by LPF of the APM induced by i.p. injection of TGB. It has been reported that phagocytic cells in animals injected with pertussis vaccine migrated poorly into a localized inflammatory site (1, 13, 17) , and a series of experiments was performed to determine if LPF was responsible for this inhibition. The response of MNPs to an i.p. injection of TGB, a potent inducing agent for MNPs, was chosen as a model system because it is a well-studied, reproducible system in which quantitation of the response was possible (8, 38) . Four groups of mice were treated as follows: two groups of mice were injected i.v. with either PBS (group I) or LPF (group III). Two other groups were injected with TGB at 1 to 2 h after an i.v. injection of either PBS (group II) or LPF (group IV). At various times after these injections, the mice were killed, and total and differential counts were determined on cells recoverable by peritoneal lavage. The APM induced by TGB was the difference in the peritoneal macrophage count between mice which did and those which did not receive TGB. The APM for the 7-day period after injection of TGB in mice which received either PBS or 200 ng of LPF is plotted in Fig. 2 . In group II mice, there was a marked increase in the number of peritoneal macrophages, with a maximum increase of over 107 macrophages per mouse on day 5. In mice treated with LPF (group IV), the TGB-induced increase in macrophages was reduced by 78 to 94% at all times examined. Since LPF inhibited the response at all times, subsequent experiments were performed on day 5, the day of the highest macrophage response to TGB in control mice.
It is important that LPF alone had little effect on the number of peritoneal macrophages. The mean total and differential counts were determined for all mice which received PBS (group I) or 200 ng of LPF (group III) only and for which total and differential peritoneal counts were determined 5 days after injection ( Table 1 ). The differential count was not statistically different in the two groups. The total macrophage count was 20% lower in group III mice than in group I mice, but this decrease was not statistically significant and makes little contribution to the calculation of APM. It is clear that the difference in APM between control and LPF-treated mice arises from the large difference between groups II and IV.
It was observed that LPF induced an increase in circulating monocytes which peaked at day 5 (Fig. 1) , and that LPF inhibited the peritoneal macrophage response to TGB (Fig.  2) . Since others have established that the increase in inflammatory peritoneal macrophages in this model is the result of influx of blood monocytes (38, 39) , it was necessary to determine whether TGB had altered the circulation of monocytes in LPF-treated mice. The total and differential blood leukocyte counts in mice which received TGB (groups II and IV) were the same as the counts in the corresponding mice which did not receive TGB (groups I and III) ( Table 2) . Thus, injection of TGB did not change the blood monocyte count on day 5 in either control or LPF-treated mice. Therefore, coincident with a fivefold elevation in circulating monocytes in the LPF-treated mice is a greater than 75% reduction in the number of inflammatory macrophages.
Control experiments. Experiments were performed to determine whether the LPF preparation would inhibit the macrophage response after it was subjected to conditions known to abolish the leukocytosis-promoting effect of LPF (Table 3) . Such treatments included heating the sample at 80°C for 15 min or premixing LPF with the IgG fraction of a goat antibody to LPF. Both treatments reduced the leukocytosis-promoting effect and also reduced the ability of the preparation to inhibit the increase of macrophages in the peritoneal cavity induced by TGB (Table 3) . Premixing the sample with normal goat gamma globulins had no effect. The leukocytosis-promoting and APM-inhibiting properties of LPF were also examined in C3H/HeJ mice, a mouse strain generally unresponsive to the biological effects of endotoxin (22) . At day 5 in these mice, 200 ng of LPF induced a leukocytosis and significantly inhibited the TGB-induced increase in peritoneal macrophages (data not shown).
To ensure that the reduction of APM by LPF was not limited to inflammation induced by TGB, the effect of LPF on the response to other inflammatory stimuli, namely, paraffin oil and PHA, was evaluated. LPF (200 ng) also inhibited by at least 75% the increase in peritoneal macrophages induced by these stimuli (data not shown).
LPF dose response for inhibition of APM. All initial experiments were performed using an LPF dose of 200 ng. Further studies compared the doses of LPF that inhibited the MNP response to those that induced leukocytosis. Blood and peritoneal cell counts were performed 5 days after the injections. Figure 3A shows the total blood leukocyte count as a function of LPF dose in mice with or without TGB. The leukocytosis observed is typical, and is the same in mice which did and those which did not receive TGB. In Fig. 3B , the TGB-induced APM is plotted as a function of LPF dose.
LPF at doses .25 ng decreased the APM significantly, whereas higher doses (.50 ng) were required to significantly increase the leukocyte count (Fig. 3A) . This indicates that LPF doses sufficient to induce leukocytosis are also sufficient to inhibit the macrophage response to inflammation. To establish a lower limit for the dose of LPF that could inhibit macrophage accumulation, a second experiment was performed with LPF doses of 1, 10, and 100 ng (data not shown). The inhibition of APM by 100 ng of LPF was similar to that shown in Fig. 3B , whereas no significant inhibition was observed with 1 or 10 ng, demonstrating that LPF doses greater than 10 ng are required.
LPF inhibits APM only when LPF is injected before TGB. All experiments presented have used a protocol in which the inflammatory stimulus was given 1 to 2 h after the i.v. injection of LPF. Further studies used a protocol in which the interval between the i.p. injection of TGB and the i.v. injection of LPF was varied (Fig. 4) . In this experiment all i.v. injections were done on the same day (day 0 in Fig. 4 ) with a single preparation of LPF. When TGB was given 4 or 2 days before LPF, there was no significant change in the peritoneal macrophage count. This indicates that LPF did not change the population of cells already in the peritoneal cavity. If, however, LPF was given either 1 h or 2 or 4 days before TGB, there was a greater than 80% reduction of APM. Thus, even 9 days after a single injection of LPF, a significant effect was observed. This is consistent with the long-lasting effects of LPF shown in Fig. 1 (Fig. 1). (ii) Coincident with the increased number of circulating MNPs in LPFtreated mice, there was a marked reduction in the number of inflammatory macrophages in the peritoneal cavity 1 to 7 days after an i.p. injection of an inflammatory agent (Table 2 and Fig. 2 ).
The conclusion that LPF is responsible for both of these effects is supported by the fact that: (i) the LPF preparation was highly purified and migrated as a single band in polyacrylamide gel electrophoresis (34) , (ii) the preparation contained virtually undetectable levels of endotoxin and B. pertussis extracytoplasmic adenylate cyclase (19) , (iii) the effects of LPF were the same in endotoxin responsive N:NIH(S) and endotoxin hyporesponsive C3H/HeJ mice, and (iv) when the LPF preparation was treated under conditions which reduced the leukocytosis-promoting effect, the preparation no longer inhibited the APM (Table 3) .
Monocytes constitute only about 5% of murine blood leukocytes, and because it is, in absolute numbers, a minor cell type, very few studies have addressed the monocyte response to administration of pertussis vaccine or other LPF-containing preparations. Nevertheless, it is clear that LPF has a profound effect on monocyte circulation (Fig. 1) . Two other studies (15, 23) have reported that i.v. injection of mice with pertussis vaccine induced a monocytosis of similar magnitude and time course to that shown in Fig. 1 . Available data do not indicate whether LPF induced a monocytosis by stimulating monocyte proliferation, by increasing release of monocytes from the bone marrow, or by prolonging the period that the monocytes remain in circulation.
The number of macrophages at a given tissue site is determined by the kinetics of influx of blood monocytes, local proliferation, efflux, and cell death. Studies have demonstrated that the increase in MNPs during acute inflammation is primarily caused by an increased influx of blood monocytes (2, 3, 38, 39) . Since proliferation of tissue macrophages appears to have little role in the rapid increase in macrophage number, the decreased number of MNPs in the peritoneal cavity produced by the prior injection of LPF could be the result of one or more of the following: (i) toxicity of LPF for MNPs, (ii) increased efflux of MNPs, or (iii) decreased influx. The experimental results presented argue against a primary contribution of either toxicity or increased efflux. LPF (200 ng) inhibited the APM by greater than 75%, yet also produced jn the same mice, a fivefold increase in circulating monocytes. Since mice were not depleted of MNPs, toxicity seems unimportant. Additionally, even high doses (100 ng/ml) of LPF were not toxic for macrophages in vitro (19) . The results in Fig. 4 indicate that the low number of inflammatory peritoneal macrophages in LPF-treated mice was not the result of increased efflux. In those mice which received LPF when the number of macrophages in the peritoneal cavity was already elevated, there was no significant decrease in peritoneal macrophages. Therefore, the most likely explanation for the inhibition by LPF is a block of migration of monocytes into the peritoneal cavity in response to inflammatory agents, a result consistent with the observation (19) that LPF specifically inhibited macrophage migration in vitro. The elevated monocyte count may also result, at least in part, from an inhibition of monocyte diapedesis. The inhibition by LPF of the in vitro migration of a cloned macrophage-like cell line (19) suggests additionally that the in vivo inhibition of APM could be at least partially explained by a direct effect on MNPs. However, the in vivo response to inflammation is a complex, cascade process involving a number of cell types, and there is no direct evidence that the primary site of LPF action in this model is the MNP. A definitive answer awaits future study.
The demonstration (Fig. 1) that LPF increased the absolute count of monocytes, PMNs, and lymphocytes suggests that LPF acts on all leukocytes through a similar site or mechanism of action. The mechanism by which LPF increases the monocyte or PMN count is not known, but it is Fig. 1 , and control data are the same as shown in Fig. 1 known that LPF increases the lymphocyte count not by stimulating cell division, but rather by inhibiting the homing of lymphocytes to the lymph nodes (5, 14, 25, 26, 35, 36) . Recent studies (5, 35) provide strong evidence that LPF can act directly on the lymphocyte and inhibit the migration of lymphocytes through the high endothelial venule of the lymph node. The studies with lymphocytes and MNPs suggest that LPF may lead to a generalized inhibitiont of leukocyte migration. The biochemical mechanism by which LPF affects eucaryotic cell function is rapidly being elucidated, and it has been shown that LPF inactivates, by ADP ribosylation, the inhibitory subunit of the adenylate cyclase complex in the target cell (4, 11, 16, 28) . The data presented here and in an earlier publication (19) indicate that LPF should serve as a valuable tool in probing the biochemical events regulating MNP migration, circulation, and response to inflammnation.
Available data allows us to speculate on a possible mechanism by which LPF offers a survival advantage to B. pertussis, a non-invasive organism found naturally only in the human respiratory tract (18, 29) . Lymphocytosis and leukocytosis are well-known signs of B. pertussis infection in humans and mice (18, 29, 31, 32) . Although there is no direct proof, it is likely that the lymphocytosis and leukocytosis result from LPF released from the organism during growth in the respiratory tract (30, 40) . The current results (Fig. 3) indicate that doses of LPF sufficient to raise the blood leukocyte count are sufficient to reduce the migration of MNPs into the peritoneal cavity in response to an inflammatory agent. The results of van Furth and co-workers (2, 3, 38) indicate that the source of both inflammatory peritoneal and alveolar macrophages is the influx of blood monocytes. If the ability of MNPs to migrate into the respiratory tract is inhibited, the survival of B. pertussis (or organisms causing secondary infections) could be enhanced 
